Mankind Pharma Ltd
NSE:MANKIND
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 853.1
2 792.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Earnings Call Analysis
Q1-2025 Analysis
Mankind Pharma Ltd
For the first quarter of fiscal year 2025, the company reported a steady revenue growth of 12.2% year-on-year, amounting to INR 2,893 crores compared to INR 2,579 crores from the prior year. This growth was driven by several factors, including a 1.5% increase due to higher sales prices and a favorable sales mix contributing an additional 0.6%. The chronic segment showed significant strength, contributing majorly to this revenue expansion.
Gross margins saw an impressive improvement, rising to 71.9%, an increase of 3.7 percentage points from the previous year’s 58.2%. The margin expansion was attributed to better sales pricing, favorable sales mix, operational efficiencies, and input cost savings. However, the management highlighted that the sustainability of maintaining these improved margins will be closely observed【4:0†source】.
EBITDA for Q1 FY '25 was INR 686 crores, reflecting a moderate increase of 4% compared to INR 660 crores the previous year. The EBITDA margins saw a decline of 190 basis points to 23.7% due to higher expenses related to one-time M&A activities and other nonrecurring costs. Adjusted for these nonrecurring expenses, EBITDA stood at INR 728 crores, achieving an adjusted margin of 25.2%, which aligns with the company’s guided range of 25% to 26%【4:1†source】.
The profit after tax increased by 10% year-on-year to INR 543 crores, resulting in a diluted EPS of INR 13.4 per share. Meanwhile, the cash EPS, adjusted for non-cash items like depreciation and amortization, was recorded at INR 16.1. The company also maintained a healthy net cash position of INR 3,747 crores as of June 30, 2024【4:8†source】.
The Consumer Healthcare business achieved revenue of INR 206 crores, marking a sequential growth of 32% quarter-on-quarter. Although year-on-year growth remained flat due to carve-out adjustments, the segment showed promising recovery. The operating profit margin for the Consumer Healthcare business was reported to be close to 20%, in line with the earlier guidance of high teens【4:9†source】.
The company continued to see strong volume growth in its chronic segments, specifically anti-diabetic and cardiac therapies, which posted robust growth rates of 21% and 15% respectively. Additionally, the acquisition of Bharat Serum is expected to strengthen the company’s gynecology portfolio, making it a leader in the segment and paving the way for entry into super specialty products with high entry barriers and minimal competition. This strategic move aligns with the company's goal of expanding into high-end, complex, and specialty products【4:1†source】【4:4†source】.
During Q1 FY '25, the company’s R&D expenses were INR 48 crores, accounting for 1.7% of revenue. Capital expenditure for the quarter was INR 125 crores, approximately 4% of total revenue. Both figures were within the company’s guidance. Additionally, the company launched several new divisions this quarter, causing a temporary increase in operational expenses that are expected to normalize over the coming quarters【4:6†source】.
Looking ahead, the company has retained its guidance for EBITDA margins to remain within the range of 25% to 26% for the fiscal year 2025. The focus also remains on sustaining the improved operational efficiencies and steady revenue growth while closely monitoring expenses and investments. The management is optimistic about future growth prospects, especially in the Consumer Healthcare and chronic segments, driven by strategic acquisitions and well-executed marketing campaigns【4:9†source】.
You don't have any saved screeners yet
Ladies and gentlemen, good day, and welcome to the Mankind Pharma Limited Q1 FY '25 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded.
I now hand the conference over to Mr. Abhishek Agarwal, from Mankind Pharma Limited. Thank you, and over to you, sir.
Good evening, everyone. A very warm welcome to our Q1 FY '25 Earnings Conference Call. On the call today, we have Mr. Rajeev Juneja, Vice Chairman and Managing Director; Mr. Sheetal Arora, Chief Executive Officer and Whole-time Director; Mr. Arjun Juneja, Chief Operating Officer; Dr. Sanjay Koul, Chief Marketing Officer; Mr. Ashutosh Dhawan, Chief Financial Officer; and Mr. Prakash Agarwal, President, Strategy.
I trust you had the opportunity to review the investor pack we shared earlier today. We will start with opening remarks and an overview of Q1 FY '25 from Rajeev Juneja followed by a detailed insight on the business performance from Mr. Sheetal Arora and then Mr. Ashutosh Dhawan will be sharing the key financial performance, post which we will leave the forum open for Q&A.
I'd like to remind you that some statements made during today's call will be forward-looking. For a detailed disclaimer, please refer to the investor presentation and press release available on our website.
Now I would like to invite Rajeev sir to share his comments.
Thank you, Abhishek, and good evening, everyone, and a very warm welcome to our Q1 25 earnings call. It's great to reconnect just a week after our discussion about the acquisition of 100% stake in BSV Limited.
Over the past 3 decades, our bottom-up strategy has enabled us to grow our reach from smaller towns to major cities, establishing a strong distribution network. By understanding market trends, we gradually ventured into OTC business, where our brands such as Manforce, Prega News are market leaders. This success prompted us to further expand into consumer wellness with products like AcneStar, HealthOK, Gas-O-Fast, which are also in a dominating position in the market. Our emphasis on consumer health care has elevated Mankind Pharma brand and established the company as a well-recognized household name.
While we entered, the chronic segment in 2004, we introduced our specialty business for diabetes, cardiology, urology, neurology and respiratory 4, 5 years ago to further expand and strengthen our chronic portfolio.
Additionally, we acquired Panacea Biotec, transplant and oncology portfolio and have also partnered with leading MNCs for in-licensing of niche and complex products like Symbicort, now Inclisaran, Vonoprazan, Neptaza, et cetera. This move has bolstered our presence in high-entry barrier segments and chronic therapies.
Now our acquisition of Bharat Serum will enable us foray into the super specialty products where entry barriers are very high and having complex and difficult to replicate products with less or no competition.
Moving ahead to the key highlights for the quarterly performance. During the quarter, we witnessed a steady revenue growth of 12% year-on-year with EBITDA margin of 25.2% adjusted for onetime cost and PAT margins of 19%. This quarter, we have generated cash from our operations INR 546 crores with the cash flow from operations EBITDA, ratio of approximately 80%.
As on June 30, 2024, we have a healthy net cash position of INR 3,747 crores. In terms of secondary sales, we continue to maintain our outperformance to IPM. I'm happy to highlight that now we are the second largest pharma company in terms of sales volume. This quarter, our volume growth was 1.9% versus 0.4% of IPM volume growth, indicating a strong -- our performance to IPM further, our chronic share has also increased by 120 bps year-on-year to 37%.
Our strategic collaborations have bolstered our market presence. For instance, we have launched Inclisaran, patented, injectable, in-license from Novartis with very high efficacy used for lowering hyperlipidemia, mostly prescribed by super specialty doctors, KOL doctors. This product is priced above INR 1 lakh per injection and is positioned as one of the most premium products across our portfolio.
Additionally, we have also in-licensed Vonoprazan from Takeda used by acid-related disorders including GRD. Our consumer health care business has shown recovery with subsequential growth of 32%, driven by expansion in modern trade, enabling our key brands to maintain their leading position within their respective categories.
Further, as part of our stockist consolidation, this is very important initiatives. In our consumer health care business, we have reduced a number of stockist by more than 60% from 6,500. Now 1,900 stockist as it is required for any OTC company to work are contributing over 85% of our sales in consumer side. This will help us generalize our efforts, enhance productivity.
As highlighted in the past, we are consistently delivering a high-teen EBITDA marginsin this business. Revenue from exports are up by 62% year-on-year, driven by increase in our base business, supported by curated new launches. Being an innovative pharmaceutical company, our endeavor is to constantly innovate and develop differentiated products to cater to the unmet needs of the patients.
To conclude, I extend my heartfelt gratitude to all of our stakeholders. And now I would like to invite Sheetal to provide more details on our business performance.
Good evening, everyone. Our domestic business revenue increased to INR 2,634 crores, up by 10% year-on-year, excluding OTP in quarter 1 financial year '25. This growth was driven by an increase in volumes and healthy growth in the chronic segment. According to IQVIA, we witnessed a steady secondary sales growth of 10.5% compared to 8.7% IPM growth. It is representing an outperformance of 1.2x.
As you all know, we have been a volume-focused company. Our strong volume growth during the quarter led to an increase in our market share to 6.1%, up to 20 bps year-on-year. We are now the second largest pharma company by volume in IPM with 23 brand families, each having a revenue of INR 100 crores plus in MAT June '24.
In our chronic segment, we have registered a healthy growth of 14%, surpassing the IPM corona growth by 1.3x. Our anti-diabetic and cardiac therapy contributed significantly to this growth with both segments wasting robust growth rate of 21% and 15%, respectively. This has resulted in an increase in market share to 5.1% for cardiac and 4.4% for anti-diabetes.
In quarter 1 financial year '25, we launched Symbicort range Turbuhaler, a world-renowned with higher efficacy. To further enhance and strengthen our respiratory portfolio, we have witnessed significant growth in its revenue. This aligns with our strategy to expand our presence in high-end complex and specialty product. Additionally, the acquisition of BSV strengthen our gynecology portfolio, catering to the entire women's health value chain. BSV has one of the most comprehensive fertility drug portfolio globally with a patent in 12 out of top 15 molecules.
Together, we will be ranked the #1 pharmaceutical company with the highest market share in the Gynecology segment. In quarter 1 financial year '25, our [indiscernible] portfolio has also registered a significant growth of 18% year-on-year, resulting in a market share improvement of 82 bps to 22%. We aspire to be the most preferred choice for all gynecology-related prescriptions.
Moving ahead to our Consumer Healthcare business. During the quarter, we achieved a revenue of INR 206 crores, up by 32% quarter-on-quarter and all our digital and other initiatives have largely been implemented. Despite increased completion, our targeted marketing campaigns led to sustained leadership position of our key brands in their respective category.
Our strategic new launch in the previous quarter, including Ova News, which helps detect the most fertile period of conceiving gas growth potential similar to the Prega News. During the quarter, our export revenue increased by 62% year-on-year, propelled by an increase in our base business and new launches in the past 12 to 18 months.
Our commitment to providing quality products to every citizen of the country has been recognized by the Quality Circle Forum of India, which awarded our [API] side in Behror, Rajasthan with 2 gold awards. Additionally, our Sikkim manufacturing site received 1 gold and 1 silver award for CIA Institution of Quality. We remain committed to fostering a healthier Bharat by innovating in the market and distinguishing ourselves from our competitors.
I will now hand over to Ashutosh ji, who will provide further updates on our financial performance. Thank you, very much.
Thanks, Sheetal ji. Good evening, everyone. It's great to have everyone here for our quarter 1 FY '25 earnings call. Today, I will be sharing insight into our financial performance for quarter 1 FY '25. During the quarter, we witnessed a steady growth of 12.2% in our revenue from operations, which increased to INR 2,893 crores as compared to INR 2,579 crores in Q1 FY '24. Our gross margins have increased to 71.9%, up by 3.7% year-on-year from 58.2% in Q1 effect FY '24.
This increase is primarily driven by 3 factors. Firstly, there is a benefit of 1.5% going from sales price increase, secondly, a favorable sales mix of 0.6%, primarily driven by growth in chronic segment. And the balance 1.6% is towards favorable mix on account of input cost savings as well as certain operational efficiencies.
During the quarter, we witnessed a moderate EBITDA growth of 4% with an EBITDA of INR 686 crores as compared to INR 660 crores in Q1 FY '24. This EBITDA margin decline of 190 basis points to 23.7% is due to higher expense base in this quarter. This is due to onetime M&A-related expenses and other nonrecurring costs. If we adjust the EBITDA with the nonrecurring expenses, our adjusted EBITDA is INR 728 crores and the adjusted EBITDA margin is 25.2%, which is in line with our guidance of 25% to 26%. The R&D expenses during the quarter were at INR 48 crores, which is 1.7% of revenue, and they are within our guidance of 2% to 2.5% of sales.
In terms of depreciation and amortization expenses, they have increased to INR 108 crores in Q1 FY '25 from INR 87 crores in Q1 last year due to Udaipur plant getting operationalized in Q2 FY '24 and the impact of capitalization of completed projects in the previous 3 quarters.
The effective tax rate for Q1 FY '25 is close to 19%, which is in line with our FY '24 ETR of 19%. The profit after tax increased to INR 543 crores, up by 10% year-on-year basis with diluted EPS of INR 13.4 per share of INR 1 paid. The cash EPS, which is EPS adjusted for noncash items like depreciation and amortize was at INR 16.1.
As you may be aware that we are in the process of subsidiarization of the consumer health care business and the transaction was approved by the Board of Directors in its last Board meeting, and we expect the transaction to get consummated by Q2 of FY '25. Accordingly, we are disclosing the profitability of our Consumer Healthcare business.
The operating profit of Consumer Healthcare business is close to 20%, which is in line with our earlier guidance of high teens operating margin. Our initiatives have started yielding results for the Consumer Healthcare business and the same can be observed from the sequential revenue growth of 32% reported in Q1 FY '25.
However, on a year-on-year basis, the growth is flat, because of certain carve-out adjustments in the revenue due to subsidiarization in the current quarter. If we remove those adjustments then year-on-year growth is mid-single digit. Our consistent efforts to enhance our operational efficiency has led to net cash position of INR 3,747 crores as on 30th June 2024, and the sustained operating working capital base of 45 days, which is in line with the operating working capital as at 30th June '23 on a trailing 12 months basis.
The return on capital employed, excluding cash, remains consistent at 34% level as of 30th June '24, as well as at 31st March 2024 on a trailing 12-month basis.
The return on equity ex cash remains consistent at 29% level as of 30 June 2024, as well as at 31st March 2024 on a trailing 12 months' basis.
Our CapEx spend for Q1 FY '25 was INR 125 crores, which is approximately 4% of the total revenue, which is in line with our guidance of 5% of the revenue and we expect it to be at the same level. Even in FY '24, we had our CapEx spend at 3.8% of the sales.
For the fiscal 2025, we are retaining our guidance of EBITDA margin to be in the range of 25% to 26%.
With this, we conclude our opening remarks. And now we can proceed to Q&A. Thank you. And over to you, Abhishek.
Sir, we can start with Q&A.
[Operator Instructions] The first question is from the line of Chintan Sheth from Girik Capital.
Hello, Am I audible?
A bit loud -- speak a bit loud.
Sure. Congratulations on the -- one question on the EBITDA margin, which you disclosed adjusted EBITDA margin at 25.2%. If I -- even if I adjust that our other OpEx line item seems to be a little higher, both on a Y-o-Y and Q-on-Q basis. If you look at adjusting that nonrecurring expenses, our EBITDA -- sorry, other OpEx as a percentage of sales comes to around 24.8 percentage versus previous quarter, it was around 21.8% and 21.4%, respectively, Y-o-Y and Q-on-Q. So if you can just point out anything which is -- which led to a slight sharper increase in other OpEx, because it's kind of matched whatever gross margin benefit, which we got during the quarter?
No, no, you are absolutely right in your assessment that the benefit of gross margin is getting absorbed by the EBITDA drop. And in this quarter, as if we compare it to the previous quarter, the expenses are high because there is a spike in this quarter as we have launched 4 new divisions and a certain degree of investment has gone into the same. So that's why there is a bulge in the expenses, which is getting reflected in this quarter expenses.
Okay. But do we see this recurring over this -- over the fiscal FY '25 or whether it will normalize over the course of FY '25 in the coming quarters?
So this will normalize over the coming quarters. The good part is that in spite of opening up of these 4 new divisions if you see the PCPM of the company, that has not dropped. That has increased by INR 30,000. So which is at INR 6.8 lakhs which was INR 6.5 lakhs earlier. So we expect it to normalize in the coming quarters.
Sure. And second question was on the BSV. If you -- I know we clarified around that. I just had a question on the ROCE, which you spoke during our previous interaction of the BSV division at around 15% to 16% in FY '24. If you can just clarify one part is that given the reported margins at 23%. Is this the reported ROCE profile or existed ROCE profile at the 28% EBITDA margin which the business, at the core, generated?
So thanks, Chintan, for your question. So that one is on the adjusted EBITDA margin, 15% to 18%. The way to look at it is that we are at 30% plus ROCEs. You have to look at it when we consolidate with this asset, you have to look at the consolidated ROCE how it pans out. So it would be upwards of 20%. And both the assets, we are expecting margin expansion and more so with BSCs since we believe that it is not fully penetrated not fully optimized. So we see a lot of dues there. So when we see EBITDA margin and cash flow operations improving, your ROCE is bound to improve by 100 to 200 basis points at the basic level.
And lastly, if I may, and I'll jump back in queue. On the BSV deal as well, the enterprise value of INR 13,630 crores, if you can provide what is the net debt or net cash on BSV at the time of acquisition or FY '24?
So it is a very neutralized position. So we will come back to more details when the closing happens. So we just signed the agreement. The details will come out when the closing happens.
The next question is from the line of Kunal Dhamesha from Macquarie.
Just continuing on the BSV debt, I think FY '23 that the finance expense for them was really high. So I think it will be good if you can provide some detail as to what is sitting on their balance sheet? And how is the PAT for the BSV for FY '24?
So I'll give you some color on the fiscal '24 numbers. So if you see, we have given a number of around 28% adjusted, if you see the slide where we had added Mankind plus BSV, so INR 488 odd crores, leading to 28%, plus/minus margins. So assuming 70% plus will be the cash flow conversion, you can do the math.
So quite clarify, Kunal, okay? So because it's basically from the transaction structure because Advent has done, it was a [ CCD ] structure, which was there. So because of that, this interest is getting reflected. But as the transaction will get consummated, everything is going to get converted into it. So that was more of internal debt repayment to the parent. That's why this interest spike is getting reflected.
Sure, sure. So that will reverse [indiscernible]. And I think that was mentioned, right, the callable bonds, et cetera, what is given in the balance sheet at some point, would it...
Kunal, can you speak louder, please?
That structure has it changed drastically in FY '24? Or whatever we see in FY '23 is what kind of continued and we will change it once we acquire it?
So once we acquire the whole structure is going to get converted into equity and those equity will be acquired by us. It will be plain, simple, vanilla buyout.
Sure, sure. And one more question I had, since we have seen good traction in chronic therapies now, we are almost at par with the market level penetration in terms of chronic, right, market is at 38%, 37%. Would you be able to quantify the kind of EBITDA margin difference between our chronic business versus the acute business stuff?
No. So it's basically a mixed up Kunal that -- we don't track EBITDA. We only track it at a particular level, but not at the EBITDA level, the acute versus chronic because in some of the divisions, [ MR ] is promoting both the products. So it's difficult to do a segmentation at that level.
But it's fair to assume that obviously the gross margins are much higher in chronic?
Correct. Correct. And what that difference would be in the gross margin between chronic and acute problems?
So it has increased up to 15% now, yes.
Despite we launching the DMF-grade APIs, et cetera?
Yes.
Sure. And on the DMF-grade API, I think we had a plan to launch around 1,200 SKUs and we had done some 325 maybe till last quarter. So where are we on that now?
So last quarter, we have announced that we have done approximately 150 DMF filings. This quarter, we are close to 160.
Okay. And sir, in terms of SKUs how would it mean because there will be multiple SKUs?
We are not splitting by SKUs.
Sure, sure. And the last one, if I may. We have done a lot of in-licensing deals, right, starting with Neptaza, et cetera. What would be the contribution of the in-licensed product for us over the last 12 months? A rough number is fine.
See the first one happened in '22, '23. So the contribution has just started. The idea is to get the foot in the door of the specialty doctors. While the sales are growing at 30%, 40% or even more, but it is on a small base. But it gives a lot of synergy benefits of our core portfolio also. So you have to see that in entirety. But coming back to your question, on a small base, it is still growing at 30%, 40% plus.
Okay. But it is fair to assume it will be single-digit contribution as of now?
Not even 1%.
It is fairly less at the moment, and it will not be a correct reflection of that because these in-licensing deals have been done at a different point of time. So they have not been for the whole year, so that the real basis can be drawn from -- or inference can be drawn from the same. So maybe a year or so, it would be in a position. But at this stage, it will not give the correct reflection of things.
So major reason of the in-license deals basically is what advantage to Mankind is, we get an intangible hike in reputation of Mankind, one. And wherever we -- basically our endeavor were to really enter those high-end doctors, high-end hospitals, we get welcome over there, foot in the door, that's a major thing. That's the reason. And we basically want to enter difficult to make or high-entry barrier or in-license, where instead of 30, 40 competitors, we have 2, 3 competitors.
So we just want to enter that market and attain some kind of a, I mean, position over there because tomorrow, more products will come. So it's like I think [accommodating] yourself, your feel for that kind of environment.
Sure, sure. So that then you can cross-sell your existing portfolio, which is anyway high margin and can bring that synergy side?
Yes.
The next question is from the line of Neha Manpuria from Bank of America.
Ashutosh sir, on the gross margin, most of the factors that you mentioned, sales mix can change seemed very sticky. Obviously, I understand there is seasonality in the business. Adjusted for that, is it fair to assume that this level of gross margin is sustainable for Mankind?
That's a good question, Neha. So we would say that 70% would be the fair assumption to assume it around 70% level because 1.6%, which is coming from the input cost savings, that's a timing difference, which could -- it's not in our control, to be honest. And because of the capacity utilization and all, so this time, the margin is higher. But from the sustainability point of view, we are more confident or comfortable with 70% gross margin level.
So Neha just to add, if you're doing some modeling purpose, 70% is good, but at the same time, as one of the participants asked on the cost side. So we do expect cost to normalize. So you will see the cost going down and there's a corresponding effect on the EBITDA.
No, no. That is understood. I was just trying to get clarification because the margins had improved so much. So I just wanted to get a sense there. My second question, on the BSV deal, the 16% growth that we had mentioned, right, adjusted for their acquisition and COVID. If you were to break that up between international business and domestic, what would be the growth, let's say, in the domestic business and international? Because I think the international growth that you've mentioned is in constant currency, but on a reported basis, what would that growth be?
Yes. So we have given a growth of around 17%. That would be India, 16% to 17% and 25% plus is -- around 25% in constant currency growth for international business.
So the reported is also in the same range?
Reported is actually a tad better...
Oh, it's tad better.
Because of the TTK acquisition, it is a tad better.
No, no. Sir, the 17% -- the 16% growth is excluding TTK, right?
It's actually 17% pro forma. So on that, there's about 9% volume, 6%, 7% price, 1%, 2% -- 1% here in there. So new product is about 1% to 2%. So it's not 16%, it's 17% and pro forma growth that we had given in the presentation pack is 21%.
[Operator Instructions] The next question is from the line of Tushar Manudhane from Motilal Oswal Financial Services.
Sir -- Rajeev sir, first at the industry level. We are seeing this volume growth remaining quite muted, even FY '23, hardly 0% even FY '24, 0.9% or even 1Q FY '25 to be like 0.9%. So this shift towards trade generics. So will that sort of further reduce overall industry growth for next, let's say, 3 to 4 years, if you could share some comment on this?
See, I mean it's a mixture of things. One basic is that seasonality also plays a role because whatever unit growth comes, there is always a contribution of antibiotics or acute side of the business as well. Yes, you're right as well. I mean some kind of stress is there from generic kind of players as well. It's a mixture of things.
Yes, just to add, there is one more issue which we need to take into account that 6% contribution of modern trade is not being captured by IQVIA. That is why there is under reflection of volume growth as per IQVIA is concerned.
No, no. So I mean to refer the prescription side of the overall market. So there, we will see growth is getting much more moderated to the way it is like -- it seems over the next 3 to 4 years, it could go down to 6% or so.
Try to understand one more thing that wherever a prescription comes from the hospital, it is not being maybe tracked. And one more thing is there that hospital side, patients are more than general practitioners. I mean whenever you see, you go to a hospital, you find more patients. Otherwise, in normal clinics, when season comes, then you see a good number of patients. That is also an impact.
Understood, sir. Secondly, as far as the metro Tier 1 share is concerned for Mankind, despite a good number of niche products being added, the chronic share being rising, the metro Tier 1 share remain still stable for last 2, 3 years. So just to understand if I'm missing any.
See, our metro and Class 1 share is around 53% -- yes. So there is still scope for improvement. The good thing is that both metro town on we are growing at much better pace as compared to IPM growth. So we are bridging the gap between IPM, contribution of metro and Class I and Mankind.
And Tushar, if you see last 4 years growth of metro, IPM is close to 10% to 12%, but IPM growth is somewhere in the range of 11% to 20% for metros -- our Mankind metro.
How much is it for Mankind?
For Mankind it is in the range of 11% to 20%, you can refer last quarter presentation where we have highlighted that our metro share has increased from 51% to 55% in the last 4 years, chronic metro share.
The next question is from the line of [ Sumit Joshi ] from [indiscernible] Finance.
Hello, sir, can you hear me?
Yes, Mr. Joshi.
Yes, we can hear you.
Yes, yes, yes. Sir, I'm just asking a very high-level question, maybe from a 2 to 3 years the way we want to grow a product strategy right after the acquisition. Is there something big picture, which we are planning that we can give some guidance that will help me to understand better?
See, I mean, the big picture basically is what -- look at the history of Mankind, 5 points were there always in our head. First was a bottom-up approach. Second was our OTC business. Third was making mankind brand a household brand. Next was chronic side. After that, we entered into super specialty and then now super specialty. So it's like I mean completing the pyramid -- coming to the high end of the pyramid.
And ensuring that we are in every side of the pharma market and growing in the fastest pace. And hopefully, I mean, we'll do fantastic. Because going forward, as a number of times, these questions keep coming that there is a stress because of generic, because what we basically see generally, whenever you bring some product or one product which basically comes out of patent, 40, 50, 100 competitors come immediately.
And our intentions of taking this BSV is what that we should be in complex business. We should be difficult to make products, we should make the high-entry barrier products, where advantage is either you are alone, either you have some kind of a monopoly or 1 or 2 competitors, that's plus side. You can command the prices. You have more EBITDA margin. That basically is our hopes. Keeping those planning in mind, we have just acquired this company. And what we basically hope, we have said a number of times, this business is multiplying in coming future.
Okay.
We are very, very, happy and confident that this is a fantastic buying of Mankind. I mean, nothing can be better than this one because everything fits very, very well in Mankind. Look from any angle, every corner whether the consumer side, I mean, Ossopan or [indiscernible], whether it's a patent product, and tidy, high-entry barrier, whether you look at this Thymogam, again, 100% market share, some [ antibiotics ] with 98% share or in this in fertility, we have 1 or 2 competitors. It's amazing, amazing kind of a -- we feel, I mean, we've done a fantastic job by acquiring this. Absolutely confident and pretty sure about this business.
[Operator Instructions] The next question is from the line of Nikunj Doshi from Bay Capital.
Just one question. Are we expecting any more merger-related costs in the next quarters?
Yes. So the transaction has started in a way at the end of the last quarter. So we have -- so there will be certain merger-related costs, which will be coming in this Q2 as well.
So just to be clear, Nikunj, the cost that you are seeing in Q1 is related to the transaction that we saw in Q1.
Okay. Okay. So this larger transaction, what we are doing, that will be further in...
That will be in Q2.
The next question is a follow-up question from the line of Kunal Dhamesha from Macquarie.
Just on this, the BSV growth split between India and international, I probably misunderstood it. Total growth is 16% adjusted for the acquisition. And then you are seeing India grew at 16% and international was better than 25%. So I...
So Kunal, if you should see the presentation, we have given a 21% CAGR growth. We are giving a split of India and international, which is India is 17% and international is 25% dollar-term growth.
Okay. So 21% is not adjusted for TTK. So TTK is more in the international...
No, no. TTK is a domestic business. So what has happened is, why we have given pro forma numbers, there is a volatility due to the COVID-related products and the TTK related products. So we have neutralized that. If you see on a reported like-to-like basis, growth is actually 24%, but we did -- we wanted to give a pro forma numbers for the right reflection for future. Does that help?
No, but the COVID would have also positively impacted during the initial phase?
No. But then there are spikes and there are peaks and valleys, right? So 1 year, you will see a spike, then other years, it will go down. So we have removed the volatility.
But in CAGR, you will only look at the first and the last year, right? The spike will not...
So '21 was higher, right, because of the COVID year?
Correct. '21 also, there were lockdowns. So yes, difficult to understand. Can you help us with a slightly larger -- longer-term growth rate for the BSV?
So we have called out that the growth will be in the region of 15% to 20% is what we believe, it can be even better. I mean this is our initial assessment. And we have also called out that we look at margins around 30% plus and to improve year-on-year.
So if you look at the audited reported CAGR, that is 23% and the adjusted is 21% adjustment for the COVID.
Okay. And one question on the overall market in response to the previous answer. So you said the 6% of the modern trade is not getting reflected in IQVIA. My question is how fast that 6% is growing. And since it is not getting reflected, what are we missing from the IPM growth? And what is our exposure to that modern trade channel now? I think we had a good quarter, a couple of quarters back or something. So are we like now under-index, over-index or we are properly indexed with respect to that 6% of the market.
So as per my understanding, 6% contribution comes in IPM from modern trade. That is having growth that there is no channel to give us the correct growth, but as per different sources, the growth comes to around 15%. So as per Mankind is concerned, our contribution from modern trade is around 4%.
4%. So still there is scope for us to kind of find more -- penetrate more in this channel. Sure, sure. And one question on the Panacea acquisition that you had done, right? How is that now -- it is some time that we have been with this business -- how has that kind of grown what we have seen in terms of the improvement in terms of profitability, any synergies that you have seen? If you can provide some update there, it would be good.
So Panacea business has already panned very, very well. On one side, again, super specialty business when we acquired Panacea, the thoughts were same, absolutely same kind of thoughts. Transplant business, super specialty difficult to enter, one, that is being very good, Glizid antidiabetics, more than INR 100 crores brand now. And apart from this Sitcom is a patent product that we acquired. So all in all, the Panacea business must be growing at a pace of 20%, 25% right now.
33%.
33%.
[indiscernible] % plus in terms of profitability also. Even though Panacea has been fully submerged into all the divisions wherever there was energies are there, but on a very broad basis, the EBITDA margin is also close to 30% coming out of that -- the product of Panacea.
And if you extrapolate Panacea, by many times, this would be -- Bharat Serum even better. And if you remember very well when Panacea was acquired, I mean, people were saying it's expensive this and that, but we knew our business.
Okay. Sure, sure, sir. And one for Ashutosh ji. On the R&D expense, it seems lower for this quarter, right? So do we expect to ramp up? Or do we see that R&D expense overall would be more or less flat for FY '25 over FY '24...
So we would like to retain the guidance of close to 2% because R&D is mainly driven from some of the project related and the testing related expenses. So there are sometimes some spikes here and there, but by and large, as a rule of thumb, expected to be around 2% level.
So it should see similar growth as to our top line more or less in FY '25. Last year was 2.2%, I guess, so.
So this time also, it will be in that vicinity only.
[Operator Instructions] The next question is from the line of Prashant Kothari from Pictet AMC.
The first question is on the BSV acquisition itself. In terms of funding for it, I understand you're not kind of properly finalized. But just looking at the overall numbers, it seems that if you were to apply that discipline of 2x net debt-to-EBITDA, if you could just kind of wait until the FY '26 end then you would already be kind of in that limit even if you don't dilute. So just wanting to understand how you're kind of thinking about the need for equity dilution versus maybe waiting a bit so that it's not needed actually?
Yes. So the rough broad math could be thought like this, that we are looking to fund this, as Rajeev ji mentioned on the Friday call, that around INR 4,000 crores could be used approximately from the internal accruals. So we are -- from the remaining, the majority would be a mix of debt and equity and the majority would be debt. But we believe since we've always been a conservative company, there will be a requirement of equity, which could be in the region of about 30%.
Right. So INR 4,000 crores internal accruals we'll have in the next 2 years, plus, we have INR 3,500 crores of net cash.
No, no Prashant. So by the -- around closing, we would be having that kind of cash. So we will be using that cash to pay upfront, that's one. The remaining that we are required to pay, which will be a mix of debt and equity, majority will be by debt given the cash flows that we have. We believe that we'll be able to take a majority of it is debt. But since we want to have a lighter balance sheet, we don't want to leverage significantly. And as per our guidance, of debt-to-EBITDA of not exceeding 2x. We think that we would be looking at plus/minus 30% of equity risk and that would be around closing.
Okay. Okay. So the EBITDA you're looking for that calculation is of FY '25 itself?
Can you repeat?
On a combined basis -- the EBITDA that you're using for that calculating...
Yes, '25 and '26. And on a conservative basis, we are calculated. So obviously, the business could give a bit better returns. But these assumptions are based on conservative estimates of mankind as well as BSV.
Understood. Understood. And sir, the second question was on market growth differential official between the kind of metro Tier 1 versus the rest more rural semi-urban, how much is the differential these days? Has it changed versus the past?
So if we talk about IPM versus Mankind. So a Q-on-Q basis, quarter -- Q1 basis, rural has -- as per -- IPM has grown by 6.7%, Mankind is growing by 10.3%. And town 1 is growing by 10.4% as per IPM is concerned, and Mankind growing by 12.7%. Metro and town 1, in total, is growing by 9.3% as per IPM is concerned and Mankind is growing by 10.6%.
So rural, as per IPM is growing the slowest, why is that happening? And is that just recent or that has been the trend in the last few quarters also?
So FY '24 as well, rural has shown a growth of 5.9%. So this quarter has been better as per FY '24 is concerned.
Yes. But it is growing slower versus the overall market. So just trying to understand what is happening there in terms of the overall pharma sales, not for you, but for the industry?
So rural, usually -- market, usually, the growth you see whenever season, there's a seasonal impact because rural market is all about acute segment rather than chronic. So last year, the acute season came very late in the month of October only. That is why we had muted performance of acute segment overall in the year and it impacted the rural growth.
Prashant, if I can add. So if you see the number of doctors who are available, the number of chronic diseases, which are growing faster than the market and acute is happening more so in the metro and Tier 1 cities. So the growth share in metros and Tier 1 is higher versus rural.
Okay. Which is what I was trying to kind of think of whether it is that the companies are not making enough efforts? Or is it just about the doctor population, wherever they grow the market grows, how should I kind of...
Again, Prashant, India is a land of many cities, towns, rural is like rural and then above rural, it would be again segmented into 3 sub-buckets. So the first bucket is metro and town 1. The second bucket is town 1 and town 2, which is Tier 1 and Tier 2 cities. And then there's a third bucket above rural, which is town 2 to town 4.
So this is split again into 4 big buckets and rural is a part of it. So metro and Tier 1 is totally where everybody is really focused on. And I think we, as Rajeev ji mentioned, we have always gone bottoms up. So we started with actually not rural, but town 2 to town 4. And then we have picked 2 Tier 1 cities and now metro and Tier 1. So it is bottoms up for us.
And to add to Prakash point because of the lifestyle changes, the chronic diseases are more prevalent. And because of the hygienic people are in rural area, people are more aware about hygiene, cleanness drives. So that's why acute is growing less and people are -- that's where you see the growth of chronic more -- even in more, even in IPM also.
Interesting. And sir, just the last question of our growth, how much is pricing?
Sorry?
Because of -- pricing is 5.8%. Our volume growth is 1.9%, and growth because of price increases 5.8% and growth because of new products is 2.7%.
The next question is from the line of Gagan Thareja from ASK investment managers.
Sir, I have one question pertaining to the split of the acquired asset value of BSV into fixed tangible assets, intangibles and goodwill. If you could give a broad rough split, that would be very helpful.
Yes, Gagan, this is an extensive exercise, which will be carried out closing -- at the time of closing and after closing. But just to give you a sense since it's a high-entry barrier and a niche asset, the majority of the allocation will be towards the intangible side. Close to around 60% to 70% would be the portion, which may get allocated towards the intangibles.
And when you say intangibles, I mean, because intangibles would include patents, trademarks plus goodwill life. I'm presuming that is how it is. So from the perspective of depreciation and amortization, it's is going to be trademarks and patents which will be amortized, goodwill will not figure there. So I'm just trying to understand that split further down.
Correct. So goodwill will not be getting amortized but intangibles in terms of technical know-how, trade, brands which are coming with this and plus some other intangibles will also come, customer relationship, et cetera. So all those things will be getting amortized over a period. So how much will that period will be and the exact quantum of that intangible that is subject to export valuation.
But from the broad indicative point of view, it will be closer to 60% of the intangibles and the balance would be towards the goodwill. But this number may get highly likely to get changed once the proper PPE exercises carried out by the experts.
Right. And Rajeev, sir, I think in your interview to Business Standard have indicated that BSV sales could touch INR 5,000 crores sort of mark in the next 3 to 4 years. To whatever degree possible, would you be able to explain how you think you can bring this about what could be the broad contours of the strategy here?
Sometimes, I mean, journalists are also very, very enthusiastic. They basically add some kind of flavor. I mean the expectations are very, very high from this company. I said basically in 4, 5 years, maybe roll down 3, 4 years. understand the point, in some of the categories, there is no competition.
Just example, anxiety is one product, which in India, approximately 5% to 7% ladies who want to be mother are RS negative, right? That is approximately 90 lakh to 1.2 crores. But how many injections are being sold right now? 9 lakh. So right now the coverage is -- penetration is only 10%. If we increase the penetration to 20%, the market can grow double, 30% more. It's a matter of just propagating it, matter of just making sure that people have this kind of a knowledge, just example. And they have patent on this product in 2028.
And also, within in a number of countries, other countries as well, same is the situation. So this company comes with a very high-entry barrier products, one. The second basically is what just look around yourself. This particular segment is growing fastest, infertility. You go in bigger towns, smaller towns, every place, every gynecologist wants to open a fertility clinic. That is one area which is growing very, very fast because of urbanization, because of women empowerment, because late marriages, a lot of reasons are there, right?
You see from any angle, I mean, this company has all their plus sites. Tailwinds are also -- complexities are there, difficult-to-make products are there, patent products are the. So this way, we expect this company can grow a lot, very, very optimistic.
The next question is a follow-up question from the line of Chintan Sheth from Girik Capital.
Yes, sir. On the export side, if you look at the growth has [picked] as well on a high base, do you see the run rate of the current quarter can sustain or do you see as quarter progresses, we will see some softness at least the rate of growth can taper a bit low going forward? How do you see the exports panning out?
See, because of the low base last year quarter, so growth is high, extreme high in this quarter. But as always, maintain in the commentary that Mankind business will mostly focus in domestic, almost 90% business of domestic one.
Okay. But at the 15% mid-teen growth, which we gave, that is what we should work with...
No, I think that the growth will continue. For an export side, the growth of quarter-on-quarter will continue, that's what has been guided so far.
Okay. And one clarification. You mentioned on the deal, 30% equity is on the deal side, the 30% figure you mentioned sometime in the previous commentary.
Can you repeat your question?
On the BSV deal side, you mentioned something around a 30% figure for the equity part, the fresh equity part. Is that correct understanding?
No, somebody had asked the question around how would the funding look like? Because everything is subject to closing. So I was -- we have received many calls and e-mails from analysts trying to understand for modeling purposes, how to think about it of the asset.
We are just a little bit modeling ourselves that around 4,000 -- approximately INR 4,000 crores would be funded through internal accruals. That is the cash that we would have in the books by the time the closing happens. The remaining would be a mix of debt and equity. Out of that, the majority will be debt and the remaining, which we believe could be done with around 30%. Again, this could be changed subject to closing, but this is our initial assessment.
That was the last question for the day. I now hand the conference over to the management for closing comments.
Thank you. And please feel free to write to us for any further clarification or information. Have a nice day.
On behalf of Mankind Pharma, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.